141 related articles for article (PubMed ID: 28992737)
1. Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
Stassinos G; Klein-Schwartz W
Clin Toxicol (Phila); 2018 May; 56(5):355-359. PubMed ID: 28992737
[TBL] [Abstract][Full Text] [Related]
2. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
3. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pediatric atypical antipsychotic exposures reported to U.S. poison centers.
Stassinos G; Klein-Schwartz W
Clin Toxicol (Phila); 2017 Jan; 55(1):40-45. PubMed ID: 27644404
[TBL] [Abstract][Full Text] [Related]
5. Characterization of intentional lurasidone ingestions using the United States National Poison Data System.
Weiss SJ; Cueto-Vilorio VA; Dharmaraj R; Barolia D; Nashat A; Walsh SJ; Simpson SE
Clin Toxicol (Phila); 2020 Dec; 58(12):1342-1346. PubMed ID: 32167797
[No Abstract] [Full Text] [Related]
6. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
7. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Danek PJ; Wójcikowski J; Daniel WA
Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
[TBL] [Abstract][Full Text] [Related]
8. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Bobo WV
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and clinical outcomes of paliperidone exposures reported to U.S. Poison Centers.
Tsay ME; Klein-Schwartz W; Anderson B
Clin Toxicol (Phila); 2014 Mar; 52(3):207-13. PubMed ID: 24580061
[TBL] [Abstract][Full Text] [Related]
10. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
11. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.
Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Clin Neuropharmacol; 2013; 36(6):223-38. PubMed ID: 24201235
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.
Greger J; Aladeen T; Lewandowski E; Wojcik R; Westphal E; Rainka M; Capote H
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):5-12. PubMed ID: 33177350
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of acute exploratory pediatric lithium ingestions.
Minhaj FS; Anderson BD; King JD; Leonard JB
Clin Toxicol (Phila); 2020 Sep; 58(9):881-885. PubMed ID: 31913731
[No Abstract] [Full Text] [Related]
14. Update on newer antipsychotic drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Apr; 49(4):13-5. PubMed ID: 21446639
[TBL] [Abstract][Full Text] [Related]
15. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
Citrome L
CNS Drugs; 2013 Nov; 27(11):879-911. PubMed ID: 24062193
[TBL] [Abstract][Full Text] [Related]
16. Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.
Boyda HN; Procyshyn RM; Pang CC; Hawkes E; Wong D; Jin CH; Honer WG; Barr AM
PLoS One; 2013; 8(1):e53459. PubMed ID: 23326434
[TBL] [Abstract][Full Text] [Related]
17. 2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report.
Mowry JB; Spyker DA; Brooks DE; Zimmerman A; Schauben JL
Clin Toxicol (Phila); 2016 Dec; 54(10):924-1109. PubMed ID: 28004588
[TBL] [Abstract][Full Text] [Related]
18. Newer antipsychotics and upcoming molecules for schizophrenia.
George M; Amrutheshwar R; Rajkumar RP; Kattimani S; Dkhar SA
Eur J Clin Pharmacol; 2013 Aug; 69(8):1497-509. PubMed ID: 23545936
[TBL] [Abstract][Full Text] [Related]
19. Human bromethalin exposures reported to a U.S. Statewide Poison Control System.
Huntington S; Fenik Y; Vohra R; Geller RJ
Clin Toxicol (Phila); 2016 Mar; 54(3):277-81. PubMed ID: 26860212
[TBL] [Abstract][Full Text] [Related]
20. Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).
Mandrioli R; Protti M; Mercolini L
Curr Drug Metab; 2015; 16(2):141-51. PubMed ID: 26033329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
